Soleno Therapeutics to Participate in Upcoming November Investor Conferences
Soleno Therapeutics (NASDAQ: SLNO), a clinical-stage biopharmaceutical company focused on rare disease therapeutics, has announced its participation in three major healthcare investor conferences in November 2024. The company will present at the Guggenheim Healthcare Innovation Conference (Nov 11, 10:00 AM ET), Stifel 2024 Healthcare Conference (Nov 18, 4:45 PM ET), and Jefferies London Healthcare Conference (Nov 20, 8:00 AM GT). Live audio webcasts and replays will be available for the Guggenheim and Jefferies events through the company's website.
Soleno Therapeutics (NASDAQ: SLNO), una compagnia biofarmaceutica in fase clinica focalizzata sulle terapie per malattie rare, ha annunciato la sua partecipazione a tre importanti conferenze per investitori nel settore sanitario nel novembre 2024. L'azienda presenterà alla Guggenheim Healthcare Innovation Conference (11 novembre, 10:00 AM ET), alla Stifel 2024 Healthcare Conference (18 novembre, 4:45 PM ET) e alla Jefferies London Healthcare Conference (20 novembre, 8:00 AM GT). Saranno disponibili webcast audio dal vivo e registrazioni per gli eventi di Guggenheim e Jefferies attraverso il sito web della compagnia.
Soleno Therapeutics (NASDAQ: SLNO), una empresa biofarmacéutica en etapa clínica centrada en terapias para enfermedades raras, ha anunciado su participación en tres conferencias importantes de inversores en el sector de la salud en noviembre de 2024. La compañía presentará en la Guggenheim Healthcare Innovation Conference (11 de noviembre, 10:00 AM ET), en la Stifel 2024 Healthcare Conference (18 de noviembre, 4:45 PM ET) y en la Jefferies London Healthcare Conference (20 de noviembre, 8:00 AM GT). Habrá webcasts de audio en vivo y repeticiones disponibles para los eventos de Guggenheim y Jefferies a través del sitio web de la compañía.
Soleno Therapeutics (NASDAQ: SLNO), 희귀 질병 치료를 전문으로 하는 임상 단계의 생명공학 회사는 2024년 11월에 있을 세 가지 주요 의료 투자자 회의에 참석할 예정이라고 발표했습니다. 이 회사는 Guggenheim Healthcare Innovation Conference (11월 11일, 오전 10시 ET), Stifel 2024 Healthcare Conference (11월 18일, 오후 4시 45분 ET), 그리고 Jefferies London Healthcare Conference (11월 20일, 오전 8시 GT) 에서 발표할 것입니다. Guggenheim과 Jefferies 이벤트에 대한 라이브 오디오 웹 캐스트 및 재생이 회사 웹사이트를 통해 제공될 예정입니다.
Soleno Therapeutics (NASDAQ: SLNO), une entreprise bio-pharmaceutique en phase clinique focalisée sur les thérapies pour les maladies rares, a annoncé sa participation à trois grandes conférences d'investisseurs dans le secteur de la santé en novembre 2024. La société présentera à la Guggenheim Healthcare Innovation Conference (11 novembre, 10h00 ET), à la Stifel 2024 Healthcare Conference (18 novembre, 16h45 ET) et à la Jefferies London Healthcare Conference (20 novembre, 08h00 GT). Des webdiffusions audio en direct et des rediffusions seront disponibles pour les événements Guggenheim et Jefferies via le site web de l'entreprise.
Soleno Therapeutics (NASDAQ: SLNO), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf Therapeutika für seltene Krankheiten konzentriert, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im Gesundheitswesen im November 2024 bekannt gegeben. Das Unternehmen wird auf der Guggenheim Healthcare Innovation Conference (11. November, 10:00 Uhr ET), der Stifel 2024 Healthcare Conference (18. November, 16:45 Uhr ET) und der Jefferies London Healthcare Conference (20. November, 8:00 Uhr GT) präsentieren. Live-Audio-Webcasts und Aufzeichnungen werden für die Veranstaltungen von Guggenheim und Jefferies über die Website des Unternehmens verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that management will participate in the following upcoming investor conferences:
Event: Guggenheim Healthcare Innovation Conference
Date: Monday, November 11, 2024
Time: 10:00 AM ET
Event: Stifel 2024 Healthcare Conference
Date: Monday, November 18, 2024
Time: 4:45 PM ET
Event: Jefferies London Healthcare Conference
Date: Wednesday, November 20, 2024
Time: 8:00 AM GT
A live audio webcast and replay of the Guggenheim and Jefferies events will be available in the Investors section on the Company’s website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company recently submitted an NDA to the FDA, supported by its Phase 3 development program, for its lead candidate, DCCR (diazoxide choline) extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS). For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
When is Soleno Therapeutics (SLNO) presenting at the Guggenheim Healthcare Conference in 2024?
Which investor conferences will Soleno Therapeutics (SLNO) attend in November 2024?
How can investors access Soleno Therapeutics (SLNO) conference presentations?
